What the FDA labels say about taking them together
Posaconazole and vincristine
Posaconazole's FDA label of August 3, 2026 names vincristine in its drug interactions section; the vincristine label PlainMeds reads does not name posaconazole. The posaconazole label: “Concomitant administration of azole antifungals, including Noxafil, with vincristine has been associated with neurotoxicity and other serious adverse reactions; …”
Check it at the source: the posaconazole FDA label on DailyMed (effective August 3, 2026, Aurobindo Pharma Limited); the vincristine FDA label on DailyMed (effective February 17, 2026, Hospira, Inc.).
What does the posaconazole label say about vincristine?
Posaconazole label, drug interactionsVinca alkaloids (e.g., vincristine, vinblastine) Reserve concomitant use for patients with no alternative antifungal treatment options [see Warnings and Precautions (5.8) ].
Posaconazole label, warnings and precautionsConcomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions; reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
Noxafil label (Merck Sharp & Dohme LLC, February 13, 2026), warnings and precautionsConcomitant administration of azole antifungals, including Noxafil, with vincristine has been associated with neurotoxicity and other serious adverse reactions; reserve azole antifungals, including Noxafil, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options. ( 5.8 , 7.2 ) Risk in Patients with Hereditary Fructose Intolerance (HFI):
Source: FDA drug label (Noxafil, NDA022003), Merck Sharp & Dohme LLC, effective February 13, 2026 (SPL set b073b082-7b57-4423-8c06-4fd4263d6f84), via openFDA
Source: FDA drug label (POSACONAZOLE), Aurobindo Pharma Limited, effective August 3, 2026 (SPL set f8a26673-261c-4e8e-b1e1-9e23aaf7f285), via openFDA; the full label on DailyMed
What does the vincristine label say about posaconazole?
Vincristine's label (effective February 17, 2026) does not name posaconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VinCRIStine Sulfate), Hospira, Inc., effective February 17, 2026 (SPL set b22e4c8e-dbe1-4d4b-a026-e1812974071c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Posaconazole | Vincristine | |
|---|---|---|
| Labeled for | Fungal infections | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.03 per tablet 100 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once